DrugPatentWatch Database Preview
Drugs in Development Information for Simtuzumab
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Simtuzumab?
Simtuzumab is an investigational drug.
There have been 6 clinical trials for Simtuzumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.
The most common disease conditions in clinical trials are Fibrosis, Adenocarcinoma, and Pulmonary Fibrosis. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].
There are twelve US patents protecting this investigational drug and two hundred and twenty-two international patents.
Summary for Simtuzumab
| US Patents | 12 |
| International Patents | 222 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2011-06-01) |
| Vendors | 0 |
Recent Clinical Trials for Simtuzumab
| Title | Sponsor | Phase |
|---|---|---|
| Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 | Gilead Sciences | Phase 2 |
| A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF) | Gilead Sciences | Phase 2 |
| Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF) | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Simtuzumab
Top disease conditions for Simtuzumab
Top clinical trial sponsors for Simtuzumab
US Patents for Simtuzumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Simtuzumab | Start Trial | Compositions comprising oxo-derivatives of fatty acids and methods of making and using same | DS BIOPHARMA LIMITED (Dublin, IE) | Start Trial |
| Simtuzumab | Start Trial | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | Start Trial |
| Simtuzumab | Start Trial | Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same | Afimmune Limited (IE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Simtuzumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Simtuzumab | China | 107847477 | 2035-05-13 | Start Trial |
| Simtuzumab | European Patent Office | 3294282 | 2035-05-13 | Start Trial |
| Simtuzumab | Japan | 2018524274 | 2035-05-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
